Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tirapazamine · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Tirapazamine + Cisplatin | EXPERIMENTAL | - |
| Cisplatin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tirapazamine | DRUG | in combination with cisplatin and concomitant radiation |
| Cisplatin | DRUG | with concomitant radiation |
| tirapazamine (SR259075) | DRUG | - |
| Radiation Therapy | PROCEDURE | - |
| vinorelbine tartrate | DRUG | - |
Inclusion Criteria: * Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. * Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease). * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * Absolute ...
Tirapazamine is an investigational small molecule being studied for the treatment of head and neck squamous cell carcinoma, head and neck neoplasms, and lung cancer. It is in Phase 3 clinical development for these oncology indications.
Tirapazamine is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY. The drug is an investigational small molecule in Phase 3 clinical development for oncology indications.
Tirapazamine is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for head and neck squamous cell carcinoma, head and neck neoplasms, and lung cancer.
Tirapazamine has been studied in three Phase 3 clinical trials: NCT00017459 for lung cancer, NCT00094081 for head and neck neoplasms, and NCT00174837 for head and neck squamous cell carcinoma. All three trials have been completed.
Tirapazamine is also known by the name SR 4233. It is an investigational small molecule being developed by Sanofi for the treatment of head and neck squamous cell carcinoma, head and neck neoplasms, and lung cancer.